Pricing Log in Create free account

Acumen Pharmaceuticals, Inc. (ABOS) vs Pluri Inc. (PLUR)

Acumen Pharmaceuticals, Inc. and Pluri Inc. are both Biotechnology companies. Acumen Pharmaceuticals, Inc. and Pluri Inc. are of similar size ($15.5M and $15.0M). Acumen Pharmaceuticals, Inc. has the higher net margin (0.00% vs −2,344.6%) and the higher return on invested capital (0.00% vs −526.9%). Across the 15 metrics below, Pluri Inc. leads on 8 and Acumen Pharmaceuticals, Inc. on 7.

Valuation

Metric ABOS PLUR Biotechnology median
P/E n/m n/m 10.60
P/S 11.08 11.89 9.40
P/B 0.46 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.35 n/m 0.66
EV/Sales (25.36) 31.96 9.02
Earnings yield (700.36%) (197.58%) (32.88%)
Free cash flow yield (553.34%) (167.21%) (23.13%)

Profitability

Metric ABOS PLUR Biotechnology median
Gross margin 0.00% 44.59% 68.51%
Operating margin 0.00% (2,454.53%) 0.00%
Net margin 0.00% (2,344.59%) 0.00%
Free cash flow margin 0.00% (1,988.48%) 0.00%
Return on equity (162.72%) 260.35% (51.96%)
Return on assets (91.28%) (74.95%) (46.06%)
Return on invested capital 0.00% (526.92%) 0.00%

Growth

Metric ABOS PLUR Biotechnology median
Revenue growth (TTM) — (23.95%) 6.76%
EPS growth (last fiscal year) (16.96%) 31.46% 29.88%
Revenue growth, 5-year CAGR — 113.32% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ABOS PLUR Biotechnology median
Debt to equity 0.76 (1.62) 0.00
Current ratio 1.89 0.27 4.97
Net debt to EBITDA 0.69 (0.83) 1.01

Dividend

Metric ABOS PLUR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ABOS PLUR Biotechnology median
Market cap 15.46m 15.00m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack